Ballicules.com

Adenosine

ADENOCARD

Adenosine ballicule: receptor binding, kinetics and half-life diagram
Mechanism of action: Adenosine ballicule
Adenosine ADENOCARD mascot mnemonic cartoon
Visual mnemonic: Adenosine mascot
“A dino sign”

What it isEndogenous purine nucleoside acting at A1 to A3 receptors; IV bolus for supraventricular tachycardia.

Why this oneA half-life of seconds means a transient AV block that terminates re-entrant SVT and then vanishes.

What limits itGive it fast into a large vein with a flush, and warn the patient about the brief sense of doom. Dipyridamole potentiates it; theophylline blocks it.

Adenosine molecular structure (skeletal formula)
Molecular structure: Adenosine

FDA label

FDA dosingPopulationStartTargetMax
Paroxysmal supraventricular tachycardia (conversion)Adult6 mg rapid IV bolusIf no response in 1–2 min, 12 mg rapid IV bolus; may repeat 12 mg once12 mg per dose
Paroxysmal supraventricular tachycardia (conversion)Pediatric <50 kg0.05–0.1 mg/kg rapid IV bolusIncrease by 0.05–0.1 mg/kg each repeat until sinus rhythm0.3 mg/kg single dose
Paroxysmal supraventricular tachycardia (conversion)Pediatric ≥50 kgAdult dose (6 mg)12 mg if needed12 mg per dose

Renal Undefined

Hepatic Undefined

Doses greater than 12 mg are not recommended for adult or pediatric patients.

Instructions

Available strengths

Contraindications

Cautions

Adverse reactions

Pregnancy No animal or human studies; as a naturally occurring substance fetal effects not anticipated, but use during pregnancy only if clearly needed (former Category C).

Lactation Undefined

Cost

Adenosine (ADENOCARD)
Strength#/mogeneric $/unitCostPlus
3 mg/mLinjper unitnot offered
NADAC is a voluntary CMS survey of what retail community pharmacies pay for the drugs they stock. Adenosine is administered under clinical supervision and dispensed outside retail pharmacies, so it rarely appears on surveyed invoices.

NO BOXED WARNINGS

Principal riskA brief but severe sense of doom; theophylline blocks it

Classes and tags

Clinical profile

Therapeutic safety burden3 / 4
Sedation liability0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk1 / 4

Open Adenosine in the interactive console ↗